Preclinical research strategies for newly approved drugs as reflected in early publication patterns.
Naunyn Schmiedebergs Arch Pharmacol
; 389(2): 187-99, 2016 Feb.
Article
em En
| MEDLINE
| ID: mdl-26612507
ABSTRACT
The present study aimed to explore early publication patterns (i.e. up to 1 year after obtaining regulatory approval) for newly registered drugs. From the website of the US Food and Drug Administration, all newly approved drugs for 6 calendar years between 1991 and 2011 were identified. Non-clinical original publications for these compounds were retrieved from PubMed and their abstracts analysed for type of study and reported data. This yielded 170 compounds for which 1954 original non-clinical publications were identified, i.e. a median/mean of 5/11.5 publications per compound; however, number of publications per compound varied widely (0-90) and this variation exhibited a non-Gaussian distribution. The earliest non-clinical publication typically was published less than 5 years before regulatory approval and more than 5 years after filing of the primary patent, but some compounds exhibited notable deviations from this pattern. Publications most often reported on efficacy related to the target indication and on potential future indications, with fewer studies addressing mechanisms of action, potency, selectivity, pharmacokinetics and toxic effects. For most compounds, data at the cellular and in vivo level were published, with fewer reports on effects on isolated tissues and even fewer at the molecular level. The preferred species for cellular studies was human, whereas for in vivo studies, it was rats and mice. In 75 % of cases, the lead author of the publication came from an academic institution, and most studies were published in classic pharmacology journals. We conclude that number, timing and scope of early non-clinical publications on newly approved drugs exhibit major variance. Factors potentially associated with such variance are explored in a companion paper.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Publicações Periódicas como Assunto
/
Projetos de Pesquisa
/
United States Food and Drug Administration
/
Aprovação de Drogas
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Prognostic_studies
/
Systematic_reviews
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Naunyn Schmiedebergs Arch Pharmacol
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Alemanha